Renal endothelial cells (REc) are the first target of HIV-1 in the kidney. The integrity of REc is maintained at least partially by heparin binding growth factors that bind to heparan sulfate proteoglycans located on their cell surface. However, previous studies showed that the accumulation of two heparin-binding growth factors, Vascular Endothelial Cell Growth Factor-A (VEGF-A) and Fibroblast Growth Factor-2 (FGF-2), in combination with the viral protein Tat, can precipitate the progression of HIV-renal diseases. Nonetheless, very little is known about how these factors affect the behavior of REc in HIV+ children. We carried out this study to determine how VEGF-A, FGF-2, and HIV-Tat, modulate the cytoskeletal structure and permeability of cultured REc, identify key signaling pathways involved in this process, and develop a functional REc assay to detect HIV+ children affected by these changes. We found that VEGF-A and FGF-2, acting in synergy with HIV-Tat and heparin, affected the cytoskeletal structure and permeability of REc through changes in Rho-A, Src, and Rac-1 activity. Furthermore, urine samples from HIV+ children with renal diseases, showed high levels of VEGF-A and FGF-2, and induced similar changes in cultured REc and podocytes. These findings suggest that FGF-2, VEGF-A, and HIV-Tat, may affect the glomerular filtration barrier in HIV+ children through the induction of synergistic changes in Rho-A and Src activity. Further studies are needed to define the clinical value of the REc assay described in this study to identify HIV+ children exposed to circulating factors that may induce glomerular injury through similar mechanisms.
Introduction
human recombinant FGF-2 (R&D Systems); Heparin derived from porcine intestinal mucosa, USP 5,000 USP (Units /ml) APP Pharmaceuticals LLC; SU6656 (Calbiochem); C3 Transferase (List Biological Labs, Campbell, CA); Y-27632, cyclic 3'5 monophosphate (cAMP) analog, thrombin, DAPI and Beta-actin mouse monoclonal antibody (Sigma-Aldrich, MO); RO 20-1724 (MyBiosource San Diego), and RhoA (67B9) rabbit monoclonal antibody, phospo-p44/42 MAP kinase (Thr202/Tyr204), p44/42 MAP kinase, Src rabbit monoclonal antibody, phosphoMyosin Light Chain 2 (Thr/Ser 19) rabbit polyclonal antibody, Myosin Light Chain 2 rabbit polyclonal antibody, and VEGF receptor 2 (VEGFR2) 55B11 rabbit monoclonal antibody, were all obtained from Cell Signaling Technology (Danvers, MA). The anti-Rac1 mouse monoclonal antibody was from BD Transduction Laboratories™, and the phospho-Src [pY418] or (pp60src) rabbit polyclonal antibodies were from (Invitrogen). The VE-cadherin CD144 clone BV6 mouse monoclonal antibody was from EMD Millipore, MA); human Von Willebrand (vWF) antibody from DAKO (Carpinteria, CA), CD31 for R&D System for immunofluorescence, and Abcam, (Cambridge, MA) for Western blots. The goat anti-rabbit IgG-HRP and the goat antimouse IgG-HRP, were from (Bio-Rad, CA). Rhodamine goat anti-mouse, Rhodamine goat anti-rabbit, Alexa Fluor 488-labeled phalloidin, and FITC-dextran were all obtained from (Molecular Probes, Inc.)
Generation and characterization of the human glomerular endothelial cells line (HGEc-1)
Primary HGEc isolated by Cell Systems (ACBRI, Seattle, Washington USA), were characterized, and cultured as previously described [27] . To generate the HGEc-1 cell line, these cells were transfected with the pSVT vector containing the coding sequences of the SV40 large T (kindly provided by Dr. A Srinivasan, from the Wistar Institute, Philadelphia, PA), as described before [28] . Subsequently, several transformed clones were transduced with 2x10 9 particles/ml of adenoviral vectors (rAd)-carrying the catalytic subunit of human telomerase (hTERT) (from Applied Biological Materials, Inc. Richmond, BC, Canada) and cultured for 6-8 additional weeks. These cells express vWF, VE-cadherin, CD31, and VEGFR2, and formed monolayers whose trans-endothelial electrical resistance (TEER) was~60 ± 10 O /cm 2 after one week in culture. In addition, these cells responded to cyclic 3'5 monophosphate (cAMP) analogs, thrombin, and VEGF-A ( Fig 1H) in a similar manner as primary REc [29] . HGEc-1 were cultured in DMEM media with 10% FBS without endothelial cell growth factor supplements. The podocyte cell line used in this study (P-2) was generated from a child with HIVAN as described in detail before [30] . Briefly, these cells were immortalized with adenoviral vectors carrying DNA sequences encoding the SV-40 large T antigen and human telomerase. P-2 cells express the podocyte specific markers WT-1, synaptopodin, nestin, and nephrin, and show similar changes in Rho-A activity when compared to primary podocytes exposed to FGF-2 and HIV-Tat [30] . Podocytes were cultured in DMEM supplemented with 10% fetal bovine serum (FBS), 100 units /ml of penicillin, 100 mg/ml of streptozocin, and 0.25 mg/ml of amphotericine B.
Trans-endothelial electrical resistance (TEER) and renal endothelial permeability assay TEER was measured using a EVOM voltohmeter connected to an Endohm 9 electrode chamber (World Precision Instruments, Sarasota, FL) as previously described [29] . Tissue culture inserts containing monolayers of HGEc cultured on Transwell-Collagen-coated membrane, were placed in the chamber and the TEER was recorded after 10 sec [29] . The permeability experiments were done as described before [31] . Briefly, 3 x 10 5 HGEC-1 were plated onto Transwell Collagen-coated membrane inserts (Corning Costar, Cat No 3415) in DMEM media with 10% FBS, and left for 3 days to form mature monolayer with a trans-endothelial electrical resistance (TEER) of~60 ± 10 O /cm 2 . Subsequently, the cells were starved for 5 hours in serum free DMEM media without phenol red, treated with the corresponding reagents, and incubated with 1 mg/ml FITC-dextran (Molecular Probes, D-1844, Invitrogen) for 30 min at 37°C. Samples collected from the bottom chambers were read in triplicates on the Victor 3V1420 multi-counter (Perkin-Elmer, Wellesley, PA).
GST Pull-Down assays, Western blots, and transfections with Rho-A DNA construct
Rho-A and Rac1 activation was assessed by GST pull-downs using GST-Rhotekin and PAK-CRIB recombinant protein respectively bound to glutathione slurry resin as we have previously described [30] [31] [32] . Western blots were performed using standard techniques as described before [30] . Equal amount of protein (cell lysate without bound GST beads) were used to estimate total Rho-A/Rac1. Results were detected using Supersignal West Pico Chemiluminescent Substrate, from (Thermo Scientific, IL). The images were captured on Kodak film (X-OMAT) from Kodak Scientific Imaging. All experiments were repeated three times, and quantified by densitometric analysis using Adobe Photoshop 6.0. To assess the specific role of Rho-A, HGEc-1 cells were transfected using Lipofectamine 2000 (Invitrogen), with the pCEFL-MCherry control plasmid, the pCEFL-AU5-RhoAQL plasmid carrying a constitutively active Rho, or the pCEFL-AU5-RhoAN19 plasmid carrying a dominant negative mutant Rho-A. These constructs were generated and validated as described in previous studies [31, 33, 34] .
Immunostaining
Immunofluorescence studies were done as described before [31] . Changes in F-actin were assessed using phalloidin. Cell nuclei were visualized with Hoechst 33342 (Invitrogen), and observed under an Axioplan 2 (Zeiss) confocal laser-scanning microscope. Stress fibers were counted using ImageJ software.
Collection of Urine
These experiments were approved by the Institutional Review Board (IRB) of Children's National Medical Center (protocol # 00000002), and carried out in accordance with the principles of the Declaration of Helsinki. Urine samples were collected from HIV-infected children with and without renal diseases (n = 5 per group), after obtaining written or verbal consent from the patients or their parents, legal guardians, or caretakers on behalf of the younger children. An Information Sheet explaining the purpose of the study was provided in each case as requested by Children's IRB that approved the consent procedure. Urine samples were given a code number, and the records were kept anonymous to prevent the identification of the patients. Urine samples were centrifuged to clear cell debris, and the supernatants were kept frozen at -70°C until used. Samples were screened for endotoxin and those containing > 0.1 ng/μg protein were excluded. For the permeability assays the urine samples were diluted, and control and HIV+ samples containing similar values of urinary creatinine (~10 mg/dl) were compared. The urinary levels of FGF-2 and VEGF-A were measured using quantitative sandwich enzyme-linked immunosorbent assay (ELISA) kits for FGF-2 and VEGF-A (Quantikine, R & D System, Minneapolis MN, USA), as previously described [9, 35] , and the results were expressed as a ratio of the urinary creatinine values.
Statistical Analysis
All data were from at least three independent experiments and statistical analysis was performed using Prism 6. For parametrically distributed data, we used the Student's or ANOVA when more than two groups were compared. When the data were not normally distributed we used the non-parametric Mann Whitney U test, or the Kruskal-Wallis test when more that two groups were compared. P values < 0.05 were considered statistically significant.
Results

Generation of a human glomerular endothelial cell line (HGEc-1) and permeability assay
Since primary HGEc have a limited life span and require serum and angiogenic growth factors to survive in culture, we generated a HGEc line to assess the behavior of REc in the absence of serum and angiogenic growth factors. Briefly, as described in the methods section, primary HGEc were transfected with DNA carrying the simian virus 40-(SV40) T antigen and infected with adenoviral vectors carrying the Telomerase reverse transcriptase protein (TERT). Colonies of immortalized REc (HGEc-1) showing typical endothelial morphology were selected and expanded. HGEc-1 express VEGFR-2, and stained positive for the endothelial cell markers vWF, VE-cadherin, and CD31 (Fig 1) . Furthermore, they form tight monolayers in tissue culture, and show changes in permeability and trans-endothelial electrical resistance (TEER) (Fig 1) . These changes are similar to those seen in primary HGEc treated with cAMP analogues, thrombin, and VEGF-A [29] .
VEGF-A or FGF-2, in combination with HIV-Tat increases the permeability of HGEc-1 through the activation of Rho-A, phosphomyosin light chain (pMLC), and Src
Initially, we explored how VEGF-A, FGF-2, HIV-Tat, and heparin, alone or in combination, affected the permeability of cultured HGEc-1 (Fig 2) . Thrombin was used as a positive control [31] , because it induces permeability changes through Rho-A activation. Heparin was used to mimic the effects of endogenous HSPGs, which prevent the degradation of heparin binding growth factors, and could either enhance or inhibit the angiogenic activity of FGF-2 or VEGF-A [36] [37] [38] [39] [40] [41] . As described before in primary HGEc [28] , we found that VEGF-A induced modest permeability changes in HGEc-1 (Fig 2) . HIV-Tat or heparin, acting alone, did not induce permeability changes in cultured HGEc-1. However, VEGF-A or FGF-2, in combination with HIV-Tat, induced significant permeability changes that were further increased by heparin (Fig 2) . Subsequently, considering that VEGF-A or FGF-2 in combination with HIVTat and heparin induced the most significant permeability changes acting through similar signaling pathways, all follow up experiments were done in cells treated with VEGF-A+ HIV-Tat + heparin. As shown in Fig 3, we confirmed that the permeability changes were mediated through activation of the Rho-A, pMLC, and c-Src pathways, and prevented, at least partially, by C3-Transferase, SU6656, or Y-27632, which inhibited the activity of Rho-A, Scr, and ROCK respectively. In agreement with previous studies done in other endothelial cell types, we confirmed that the activation of Rho-A and Rac-1 changed in opposite directions. Moreover, we found that an active Rho-A construct was sufficient to increase the permeability of HGEc-1, although this construct also increased Src activity (Fig 4) . Taken together, our findings support the notion that cross-talk between Rho-A and Src play a critical role modulating the permeability activity of VEGF-A + HIV-Tat + heparin in cultured HGEc [24] .
FGF-2 and VEGF-A, in combination with HIV-Tat and heparin, induce the formation of stress fibers through activation of Rho-A in HGEc-1 Then, we explored whether the permeability and signaling changes described above were associated with changes in the cytoskeletal structure of HGEc-1. We found that HGEc-1 treated with thrombin alone, FGF-2 + Tat, VEGF-A + Tat, or both factors in combination with heparin, increased the number of central stress fibers running along the longitudinal axis of HGEc1 (Fig 5) . These changes were inhibited with either C3-transferase from Clostridium botulinum, which blocks Rho-A activity, SU6656, which blocks Src activity, and the ROCK inhibitor Y27632 (Fig 5) . Taken together, our findings suggest that Rho-A, MLC, and Src activation play a critical role inducing the formation of central stress fibers in cultured HGEc-1. To confirm that Rho-A activation per se affected the formation of central stress fibers, cultured HGEc-1 were transfected with DNA constructs encoding the MCherry red fluorescent protein (pCEFL-MCherry), in combination with plasmids encoding a constitutively active Rho-A (pCEFL-AU5-RhoAQL) or a dominant negative mutant Rho-A (pCEFL-AU5-RhoAN19) (Fig  6) , as described in previous studies [31, 33, 34] . These experiments showed that Rho-A activation per se induced the formation of stress fibers, both in the presence and absence of VEGF-A + Tat + heparin (Fig 6) .
Urine samples harvested from HIV-infected children with renal diseases increase the permeability of cultured HGEc-1 and podocytes through the activation of Rho-A and Src
Previous studies done in patients with HIV-renal diseases reported high plasma and urine levels of FGF-2 and VEGF-A [9, 11, 14] . Therefore we collected urine samples from HIV+ children with (HIV-RD) or without renal diseases (HIV-N), and measured the levels of FGF-2 and VEGF-A. As expected, the urinary levels of FGF-2 and VEGF-A were elevated in children with HIV-RD when compared to HIV-N (FGF-2 = 27.34 ± 17.61 vs. 3.44 ± 2,15 mean ± SD pg/μg urinary creatinine (UCr); p < 0.01; VEGF-A = 1613 ± 1590 vs. 38.40 ± 21.45 mean ± SD pg/μg UCr; p < 0.0079; for HIV-RD vs. HIV-N respectively, n = 5 per group). In addition, we found that HIV-RD samples increased the permeability of cultured renal endothelial cells and podocytes through Rho-A and Src mediated pathways that were inhibited by Rho-A, Src, and ROCK inhibitors (Figs 7 and 8 ). These changes were not affected by the low levels of endotoxin detected in the urine samples (< 25 pg/ml; S1 Fig) . Taken together, these findings suggest that FGF-2 and VEGF-A can affect the cytoskeletal structure and permeability of REc and podocytes acting through Rho-A and Src dependent mechanisms.
Discussion
Renal endothelial cells are a target of circulating viral proteins and heparin binding cytokines released by HIV-infected cells. Therefore, it is important to understand how these factors affect the cytoskeletal structure and permeability of REc. In the current study we found that FGF-2 and VEGF-A, in combination with HIV-Tat and heparin, induced cytoskeletal changes and increased the permeability of cultured HGEc acting through synchronized changes in Rho-A, Src, and Rac-1 activity. Furthermore, we found that urine samples collected from HIV+ children with renal diseases induce similar changes in cultured HGEc and podocytes. Overall, these findings suggest that FGF-2, VEGF-A, and HIV-Tat, released by HIV-infected cells, may affect the integrity of the glomerular filtration barrier acting through synchronized changes in Rho-A, Rac-1, and Src activity.
mean ± SEM values corresponding to three different Western blots that assessed the phosphorylation of Rho-A, MLC and Src in cultured HGEc-1. Results were expressed in arbitrary optical density units as a ratio of the total activity. In each group, mock, RhoAQL and RhoAN19 transfected cells were treated with either serum free media (Controls) (-), or VEGF-A + Tat + Heparin (+). Groups that were significantly different from controls (-) were labeled with asterisk, *p<0.05 and **p<0.01. Cells transfected with constitutively active RhoAQL that were significantly different from mock or RhoAN19 cells, were labeled with crosses: + p <0.05 and ++ p<0.01. doi:10.1371/journal.pone.0153837.g004 In this study, we explored the role of FGF-2 and VEGF-A, because both heparin-binding growth factors are accumulated in the kidney of children with HIV-renal diseases [9, [11] [12] [13] [14] , and affect the outcome of HIV-nephropathy in HIV-Tg mice [10, 12, 30] and rats [42, 43] . As discussed before, HSPG act as low affinity receptors increasing the accumulation of HIV-1 Tat [44] , as well as the binding of VEGF-A and FGF-2 to their high affinity tyrosine kinase receptors [6, 7] . Although FGF-2 and VEGF-A act through different high affinity receptors, there is substantial crosstalk between FGF receptors (FGFR) and vascular endothelial cell growth factor receptors (VEGFR) [45] [46] [47] [48] [49] . VEGF-A and HIV-Tat induce permeability changes acting through the KDR/Flk-1 (VEGR2) [15] . In addition, they regulate cell adhesion and angiogenic behaviors acting through α v β 5 integrins [49] , which interact with the Rho family of GTPases [50] . In contrast, FGF-2 does not induce permeability changes acting alone, but increases the permeability and angiogenic activity of HIV-Tat, probably acting through the stimulation of FGFR and VEGFR2 receptors that induce changes in Rho-A and Src activity, and the expression of α v β 3 integrins [49] . Previous studies showed that VEGF-A decreases the TEER in primary HGEc, facilitating the transit of water and small molecules, but did not increase the permeability to macromolecules [29] . We confirmed these findings, but also found that in the presence of HIV-Tat or heparin, VEGF-A increases the permeability of HGEc to large macromolecules. Heparin mimics the action of HSPG, facilitating the binding of VEGF-A to the VEGFR-2 [7] , and blocking the cellular uptake of Tat [44] , therefore, prolonging its interactions with VEGFR2 on the cell surface [15, 16] . In agreement with this notion, the most significant permeability changes were found when VEGF-A, HIV-Tat, and heparin were all used together.
The integrity of endothelial cell monolayers is maintained through the regulation of the size of intercellular gaps. This process is controlled in tightly regulated manner through changes in Rho-A and Rac-1 activity [22, [51] [52] [53] . Rho-A activation induces the contraction of actin and myosin stress fibers, increasing the centripetal tension, the size of intercellular gaps, and increasing the permeability of endothelial cells [22, [51] [52] [53] . In contrast, Rac-1 resists this tension, decreasing the permeability of REc by increasing the preservation of the VE-cadherin adherens junctions between neighboring endothelial cells [51] [52] [53] . In agreement with this notion, we found that Rho-A and Rac-1 changed in opposite directions in correlation with the permeability changes. The cytoskeletal distribution of actin and myosin fibers in cultured endothelial cells reflect this balance, centralized stress fibers indicate an increased centripetal force associated with Rho-A activation, whereas peripheral or cortical fibers reflect junctional preservation associated with Rac-1 activation [51] [52] [53] . The generation of centripetal tension is dependent on the activity of non-muscle myosin light chain (MLC) kinase, an enzyme required to phosphorylate MLC leading to the contraction of the actin-myosin fibers [54] . Rho-A regulates the activity of pMLC through a Rho-associated kinase (ROCK) that inhibits the activity of a MLC phosphatase preventing the relaxation of actin-myosin fibers [54, 55] . In support of this notion, we were able to block Rho-A-induced pMLC activation and the corresponding permeability changes with ROCK inhibitors. Of interest, Rho-A activation was associated with the loss of tight junctions in brain microvascular endothelial cells in patients with HIV-encephalitis [56] . Finally, as reported in other endothelial cell types [57] , we found that Src plays a critical role modulating the permeability of cultured HGEc-1, since both Rho-A and Src inhibitors were needed to block the permeability changes.
It is worth discussing that the permeability changes described in cultured RGEc do not mimic the in vivo situation of the glomerular filtration barrier. The glomerular filtration barrier is comprised of fenestrated endothelial cells, the basement membrane, and podocytes with their foot processes and slit diaphragms [58] [59] [60] . Podocytes play a central role regulating the permeability of the glomerular filtration barrier, and previous studies showed that the cytoskeletal properties of HIV-podocytes are impaired [61] . However, the glycocalix that covers the fenestrations and endothelial cell bodies, and the HSPG located in the glomerular basement membrane, also offer resistance to the filtration of water and small molecules [58] [59] [60] . The role of the anionic sites of HSPG is documented by the rapid effacement of podocytes in rats kidneys perfused with protamine sulfate, and by the rapid reversal of these changes within minutes of perfusion with the polyanion heparin [62, 63] . Therefore, glomerular endothelial cells and podocytes may undergo similar cytoskeletal changes in vivo, and these changes could potentially affect the size and charge of the fenestrations, the thickness of the glycocalix, and the structure and function of podocytes. Further studies are needed to confirm this notion.
VEGF-A is secreted by podocytes and transported by diffusion across the glomerular basement membrane, where it plays a key role maintaining the integrity of glomerular endothelial cells [32] . HIV+ podocytes secrete high levels of VEGF-A in the urinary space [11] . In addition, FGF-2 released into the circulation of HIV+ children is accumulated in renal glomeruli bound to HSPG [13] [14] [15] , and transported by convective flux to the urinary space. Therefore, as expected, we found high urinary levels of FGF-2 and VEGF-A in children with HIV-RD. Furthermore, previous studies showed that HIV-Tat and FGF-2, acting in a synergistic manner, increased the activity of Rho-A in podocytes cultured from the urine of children with HIVAN, and precipitated the development of HIV-nephropathy in HIV-Tg 26 mice [30] . We should mention however, that podocytes cultured from children with HIV-RD may behave differently from normal podocytes, and that more studies are needed to determine how podocytes from HIV-negative children will respond to FGF-2 and VEGF-A. Nonetheless, studies in other transgenic mouse models showed that chronic activation of Rho-A in podocytes causes proteinuria [64, 65] . Alternatively, chronic Rac-1 activation or deletion specifically in podocytes, also causes proteinuria and glomerular disease [66, 67] , and Rac-1 appears to be essential to maintain the normal structure of endothelial cells in vivo [68] . Taken together, all these findings suggest that changes in Rho-A and Rac-1 activity could play an important role in the pathogenesis of renal diseases associated with high circulating levels of FGF-2 and VEGF-A [11, 14, 69, 70] .
In conclusion, we found that FGF-2, VEGF-A, and HIV-Tat, induced significant cytoskeletal changes and increased the permeability of cultured HGEc, acting through Rho-A, Rac-1, and Src. Moreover, since other factors released into the circulation and urine of HIV+ children, including TNF-α and thrombin, are also capable of inducing Rho-A activity in endothelial cells [71, 72] , we speculate that the chronic and synergistic stimulation of these signaling pathways by multiple factors may accelerate the progression of HIV-RD in children. More studies are needed however, to define the clinical value of the REc assay described in this study to identify HIV+ children exposed to circulating factors that could induce glomerular injury through the induction of chronic changes in Rho-A, Rac-1 and Src activity.
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